Ripple Therapeutics Presents at Eyecelerator @ ASCRS 2024

TORONTO, ON, CANADA / APRIL 4, 2024 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, was pleased to present at Eyecelerator @ ASCRS 2024 in Boston.

Tom Reeves, our President & CEO, presented at Presenting Company Showcases:

 

VIEW PRESENTATION

VIEW VIDEO


About Ripple Therapeutics

Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants. Ripple’s patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading which allows for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. www.rippletherapeutics.com


Media Contact (Ripple)

Julie Fotheringham, V.P. Marketing, People & Culture, Ripple Therapeutics

M: 416-951-7988 E: jfotheringham@rippletherapeutics.com

RIPPLE-ABBVIE OPHTHALMIC DRUG DELIVERY PANEL

February 12, 2026
Our Chief Technology Officer, Wendy Naimark , was pleased to be speaking with AbbVie Directors, Allison Hoch, PhD, MBA, Director of Global Alliances and Amy Hopkin Director of Search & Evaluation for AbbVie Eyecare, on a Harnessing Innovation & Collaboration to Accelerate Ophthalmic Drug Delivery Panel at the 4th Annual Ophthalmic Drug Delivery Summit on Thursday January 29th in San Francisco, CA. 🗣️ Topic: Unlocking Biotech-Pharma Collaboration: How Agile Small Teams & Experienced Pharma Combine Strengths to Accelerate Innovation & Deliver Real-World Impact. Areas Covered: ✅ Co-developing platforms, managing device timelines and regulatory alignment in combo products ✅ Leveraging the speed and innovation of biotech startups with deep experience and resources of pharma ✅ Continuous learning through cooperation during diligence, development planning and execution phases ✅ The importance of proactive, transparent communication across functions to anticipate challenges and optimize for success View Presentation

Ripple Therapeutics Enters Collaboration with Bausch + Lomb

November 25, 2025
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.